4HRA | Crystal Structure of DOT1L in Complex with EPZ-5676 | date | 2012-10-26 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
authors | Jin, L. | ||||||||||||||
compound | source | ||||||||||||||
symmetry |
| ||||||||||||||
crystal cell |
| ||||||||||||||
method | X-Ray Diffraction | resolution | 3.15 | ||||||||||||
ligand | EP6, SO4 | enzyme |
| ||||||||||||
Gene Ontology |
| ||||||||||||||
Primary reference | Potent inhibition of DOT1L as treatment for MLL-fusion leukemia., Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, Allain CJ, Klaus CR, Raimondi A, Scott MP, Waters NJ, Chesworth R, Moyer MP, Copeland RA, Richon VM, Pollock RM, Blood. 2013 Jun 25. PMID:23801631 |
Data retrieval |
View 4HRA in 3D |
Visual 3D analysis of 4HRA |
Structure-derived information |
Sequence-derived information |
Other resources with information on 4HRA |
OCA© by Jaime Prilusky, 1996-2014,2022 Bioinformatics Unit Weizmann Institute of Science |